Displaying items 37-48 of 137
» View wsbtradio.com items only
< Previous
•
1
2
3
4
5
6
7
8
9
10
11-12
•
Next >
-
GSK opts to sell off Lucozade and Ribena drink brands
ReutersLONDON, April 24 (Reuters) - GlaxoSmithKline has decided to sell its popular soft drink brands Lucozade and Ribena in a disposal that could bring in more than 1 billion pounds ($1.5 billion). The move was announced on Wednesday alongside weak first-...Tags: New Products
-
CANADA STOCKS-TSX may open higher after Italy forms new gov't
ReutersApril 29 (Reuters) - Canada's main stock index looked set to open higher, with investors encouraged by the formation of a coalition government in Italy that ended two months of political uncertainty in the troubled region. TOP STORIES * New Italian...Tags: Kinross Gold Corporation, Gold and Precious Material, Thomson Corporation, Drugs and Medicines, Personal Income
-
Impax, GSK end Parkinson's disease partnership
ReutersApril 29 (Reuters) - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug. Impax...Tags: Diseases and Illnesses, Symptoms, Parkinson's Disease
-
FDA raises safety concerns on Valeant's seizure drug
ReutersApril 26 (Reuters) - The U.S. Food and Drug Administration said the an anti-seizure drug developed by Valeant Pharmaceuticals Inc and co-marketed with GlaxoSmithKline Plc may cause eye and skin problems. The U.S. health regulator warned that the drug,...Tags: Food and Drug Administration, Thomson Corporation, Seizures, European Union
-
Analysts see possible windfall from GSK spin-offs
ReutersLONDON, April 24 (Reuters) - GlaxoSmithKline shareholders could be in line for a possible windfall after the drugmaker put two drinks brands up for sale and bundled some 50 old drugs into a new unit, analysts said. The widely-expected sale of energy and...Tags: Imitrex (drug), Drugs and Medicines
-
GSK decide vender marcas de bebidas Lucozade y Ribena
ReutersLONDRES, 24 abr (Reuters) - GlaxoSmithKline ha decidido vender sus populares marcas de bebidas Lucozade y Ribena en una desinversión que analistas creen que podría generar más de 1.000 millones de libras esterlinas (1.500 millones de dólares). La...Tags: Lion Capital Holdings, Bain Capital, LLC
-
Fight tobacco marketing, boost vaccinations to curb cancer, says report
ReutersLONDON (Reuters) - Fighting the tobacco industry's tactics in the world's poorest countries and ensuring the best vaccines get to those most in need are key to cutting the number of cancer deaths worldwide, according to a report by specialists in the...Tags: Vaccines, Lung Cancer, Chemical Industry, Drugs and Medicines, Human papillomavirus
-
Big pharma: Few new antibiotics in the works
Thirty years ago, when the world faced the terrifying prospect of an untreatable disease known as AIDS, big drugmakers saw an opportunity and raced to develop new medicines. Today, as the world confronts the crisis of antibiotic resistance, the industry...Tags: Research, Food and Drug Administration, Research and Development, Bristol Myers Squibb Company, Companies and Corporations
-
Do soaps with triclosan do more harm than good?
If co-workers and family members are coming down with infections this winter, you may be tempted to turn to an anti-bacterial soap for protection. But some scientists are increasingly concerned that a common anti-bacterial ingredient called triclosan...
Tags: Gingivitis, Research, Rutgers University, Viral Diseases and Infections, Environmental Issues
-
State AG sues maker of diabetes drugs for false advertising
Maryland Attorney General Douglas F. Gansler said Wednesday he has filed a lawsuit against GlaxoSmithKline, LLC for falsely saying three of its diabetes drugs were better than others on the market. The company also withheld data that showed the drugs...
Tags: Diabetes, Litigation, Trials, Avandia (drug), Pharmaceuticals
-
Amgen pleads guilty, to settle misbranding case for $762 million
Biotech giant Amgen Inc. pleaded guilty to a federal misdemeanor of misbranding its anemia drug Aranesp and has agreed to pay $762 million in fines and penalties. The Thousand Oaks company said it had reached a preliminary settlement of federal criminal...Tags: Amgen Inc., Medicare, Prosecution, Trials, Anemia
-
Corporations and execs need penalties that hurt
If you're concerned about corporate crime, 2012 looked like a pretty successful year for the good guys. The Thousand Oaks biotech giant Amgen paid $762 million in fines and penalties and pleaded guilty to a federal charge related to illegal marketing of...
Tags: Trials, Prosecution, Punishment, Securities, Bank of America Corp.
Apr 24, 2013
|Story| Reuters
Apr 29, 2013
|Story| Reuters
Apr 29, 2013
|Story| Reuters
Apr 26, 2013
|Story| Reuters
Apr 24, 2013
|Story| Reuters
Apr 24, 2013
|Story| Reuters
Mar 6, 2013
|Story| Reuters
Mar 19, 2013
|Story| Reuters
Feb 10, 2013
|Story| Chicago Tribune
Feb 20, 2013
|Story| Baltimore Sun
Dec 18, 2012
|Story| Los Angeles Times
Jan 5, 2013
|Column| Los Angeles Times
Original site for GlaxoSmithKline PLC topic gallery.